Associated Papers
Differential metabolism of citalopram by 21 CYP3A4 variants: An in vitro experiment.
Wang P et al.
Journal of Psychopharmacology (oxford, England), 2025
Decoding Allosteric Effects of Missense Variations in Drug Metabolism: Afrocentric CYP3A4 Alleles Explored.
Mwaniki RM et al.
Journal of Molecular Biology, 2025
Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences.
Prost R et al.
International Journal of Molecular Sciences, 2025
In-silico screening and analysis of missense SNPs in human CYP3A4/5 affecting drug-enzyme interactions of FDA-approved COVID-19 antiviral drugs.
Abdelazim AA et al.
Scientific Reports, 2025
Effects of CYP3A4 Variants on Methadone Metabolism In Vitro.
Wang CC et al.
Biomedical Chromatography : Bmc, 2025
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Identification and Functional Assessment of Eight CYP3A4 Allelic Variants *39-*46 Detected in the Chinese Han Population.
Qi Y et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2024
The effect of gene polymorphism on ticagrelor metabolism: an in vitro study of 22 CYP3A4 variants in Chinese Han population.
Hu X et al.
Peerj, 2024
Determine the enzymatic kinetic characteristics of CYP3A4 variants utilizing artemether-lumefantrine.
Zhang X et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association, 2023
Characterization of Reference Materials for CYP3A4 and CYP3A5: A (GeT-RM) Collaborative Project.
Gaedigk A et al.
The Journal of Molecular Diagnostics : Jmd, 2023
Effects of 27 CYP3A4 protein variants on saxagliptin metabolism in vitro.
Liu Q et al.
Fundamental & Clinical Pharmacology, 2022
Why We Need to Take a Closer Look at Genetic Contributions to CYP3A Activity.
Zhai Q et al.
Frontiers in Pharmacology, 2022
Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data.
Neyshaburinezhad N et al.
Journal of Personalized Medicine, 2021
Functional Characterization of 40 CYP3A4 Variants by Assessing Midazolam 1'-Hydroxylation and Testosterone 6β-Hydroxylation.
Kumondai M et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2021
Crystal Structures of Drug-Metabolizing CYPs.
Estrada DF et al.
Methods in Molecular Biology (clifton, N.j.), 2021
Effects of 26 Recombinant CYP3A4 Variants on Brexpiprazole Metabolism.
Chen B et al.
Chemical Research in Toxicology, 2020
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Functional characterization of 21 CYP3A4 variants on amiodarone metabolism in vitro.
Yang CC et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2019
Polymorphism in Cytochrome P450 3A4 Is Ethnicity Related.
Guttman Y et al.
Frontiers in Genetics, 2019
Enzymatic Activities of CYP3A4 Allelic Variants on Quinine 3-Hydroxylation In Vitro.
Zhou XY et al.
Frontiers in Pharmacology, 2019
Functional assessment of CYP3A4 allelic variants on lidocaine metabolism in vitro.
Fang P et al.
Drug Design, Development and Therapy, 2017
Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors.
Deshpande N et al.
Meta Gene, 2016
Genetic polymorphisms of pharmacogenomic VIP variants in the Mongol of Northwestern China.
Jin T et al.
Bmc Genetics, 2016
Genetic polymorphisms of pharmacogenomic VIP variants in the Uygur population from northwestern China.
Wang L et al.
Bmc Genetics, 2015
Genetic polymorphism of pharmacogenomic VIP variants in the Deng people from the Himalayas in Southeast Tibet.
Shi X et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals, 2015
Functional gene variants of CYP3A4.
Werk AN et al.
Clinical Pharmacology and Therapeutics, 2014
Screening of Genetic Polymorphisms of CYP3A4 and CYP3A5 Genes.
Lee JS et al.
The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology, 2013
The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy.
Wang D et al.
Journal of Personalized Medicine, 2012
Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS et al.
Archives of Pharmacal Research, 2011
Evaluation of the effects of cytochrome P450 nonsynonymous single-nucleotide polymorphisms on tanshinol borneol ester metabolism and inhibition potential.
Liu D et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2010
Pharmacogenomics of CYP3A: considerations for HIV treatment.
Lakhman SS et al.
Pharmacogenomics, 2009
Ability of whole-genome SNP arrays to capture 'must have' pharmacogenomic variants.
Peters EJ et al.
Pharmacogenomics, 2008
Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics.
Deeken JF et al.
Anti-cancer Drugs, 2007
Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition.
Lee SJ et al.
Journal of Clinical Pharmacology, 2006
Screening for deleterious nonsynonymous single-nucleotide polymorphisms in genes involved in steroid hormone metabolism and response.
Johnson MM et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2005
Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype.
Lee SJ et al.
The Journal of Pharmacology and Experimental Therapeutics, 2005
CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review.
Keshava C et al.
American Journal of Epidemiology, 2004
Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos.
Dai D et al.
The Journal of Pharmacology and Experimental Therapeutics, 2001